An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Summary

The purpose of this study is to examine the impact of new cancer genetic counseling models that aim to increase patient engagement with the genetics team. To do this, the study consists of two trials to evaluate two related interventions. The first trial is the EfFORT Trial, which evaluates a cascade genetic testing intervention. Cascade testing is the process of offering genetic testing to people who are at risk of having inherited a possibly harmful gene change that has been found in their family.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• BRCA1 Mutation
• POLD1 Gene Mutation
• CDKN2A Mutation
• BRCA2 Mutation
• POLE Gene Mutation
• APC Gene Mutation
• ATM Gene Mutation
• MLH1 Gene Mutation
• BARD1 Gene Mutation
• MSH2 Gene Mutation
• BRIP1 Gene Mutation
• MSH6 Gene Mutation
• CHEK2 Gene Mutation
• PMS2 Gene Mutation
• PALB2 Gene Mutation
• EPCAM Gene Mutation
• RAD51C Gene Mutation
• BMPR1A Gene Mutation
• RAD51D Gene Mutation
• SMAD4
• PTEN Gene Mutation
• GREM1

Eligibility basics and study details

Study type

Interventional

Phase

Not applicable

Ages

25 years and older

Sex

All

Healthy volunteers

Accepted

Sponsor

Memorial Sloan Kettering Cancer Center

Last updated on ClinicalTrials.gov

August 27, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites